Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Phase 3 Study of ASP015K
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Peficitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 10 Oct 2019 Status changed from active, no longer recruiting to completed.
- 16 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Mar 2020.
- 16 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2020.